Sara R. Fagerlie, PhD, CHCP
@cancercommunicator.com
Founder of CancerCommunicator.com - Dedicated to improving the care of patients with cancer through news and clinician education.
Pinned
📢 Introducing Cancer Conference Hub
Follow real-time updates from the world’s leading hematology and oncology meetings — ASCO, ESMO, ASH, EHA, WCLC, SOHO, SABCS, AACR, and more.
👉 Explore the hub here: bsky.app/profile/did:...
Follow real-time updates from the world’s leading hematology and oncology meetings — ASCO, ESMO, ASH, EHA, WCLC, SOHO, SABCS, AACR, and more.
👉 Explore the hub here: bsky.app/profile/did:...
Reposted by Sara R. Fagerlie, PhD, CHCP
Welcome to the Science feed!
Please read our FAQs for instructions for how to be added as a contributor: bossett.io/science-feed/
Mod introductory posts linked below⬇️
Use the test tube emoji on posts you want to appear in the feed🧪
Please like the feed and make sure you follow our feed rules:
Please read our FAQs for instructions for how to be added as a contributor: bossett.io/science-feed/
Mod introductory posts linked below⬇️
Use the test tube emoji on posts you want to appear in the feed🧪
Please like the feed and make sure you follow our feed rules:
February 10, 2024 at 3:08 PM
Welcome to the Science feed!
Please read our FAQs for instructions for how to be added as a contributor: bossett.io/science-feed/
Mod introductory posts linked below⬇️
Use the test tube emoji on posts you want to appear in the feed🧪
Please like the feed and make sure you follow our feed rules:
Please read our FAQs for instructions for how to be added as a contributor: bossett.io/science-feed/
Mod introductory posts linked below⬇️
Use the test tube emoji on posts you want to appear in the feed🧪
Please like the feed and make sure you follow our feed rules:
Reposted by Sara R. Fagerlie, PhD, CHCP
#ESMO25: Peri-operative enfortumab vedotin plus pembrolizumab significantly prolonged event-free and overall survival in cisplatin-ineligible patients with muscle-invasive #BladderCancer in the phase III KEYNOTE-905/EV-303 trial
#ESMODailyReporter➡️httpsef="https://ow.ly/YVy550XeuKH" class="hover:underline text-blue-600 dark:text-sky-400 no-card-link" target="_blank" rel="noopener" data-link="bsky">https://ow.ly/YVy550XeuKH
#ESMODailyReporter➡️httpsef="https://ow.ly/YVy550XeuKH" class="hover:underline text-blue-600 dark:text-sky-400 no-card-link" target="_blank" rel="noopener" data-link="bsky">https://ow.ly/YVy550XeuKH
October 18, 2025 at 3:30 PM
#ESMO25: Peri-operative enfortumab vedotin plus pembrolizumab significantly prolonged event-free and overall survival in cisplatin-ineligible patients with muscle-invasive #BladderCancer in the phase III KEYNOTE-905/EV-303 trial
#ESMODailyReporter➡️httpsef="https://ow.ly/YVy550XeuKH" class="hover:underline text-blue-600 dark:text-sky-400 no-card-link" target="_blank" rel="noopener" data-link="bsky">https://ow.ly/YVy550XeuKH
#ESMODailyReporter➡️httpsef="https://ow.ly/YVy550XeuKH" class="hover:underline text-blue-600 dark:text-sky-400 no-card-link" target="_blank" rel="noopener" data-link="bsky">https://ow.ly/YVy550XeuKH
Lots of exciting data at #ESMO25. Here are the 3 Presidential Symposia presentations. Tomorrow: DESTINY-Breast11 (high-risk HER2+ eBC), DESTINY-Breast05 (high-risk HER2+), KEYNOTE-05 (MIBC), KEYNOTE-B96 (ovarian). #BCSM #Bladdercancer #gusm #ovariancancer #gynsm
October 17, 2025 at 7:08 PM
Lots of exciting data at #ESMO25. Here are the 3 Presidential Symposia presentations. Tomorrow: DESTINY-Breast11 (high-risk HER2+ eBC), DESTINY-Breast05 (high-risk HER2+), KEYNOTE-05 (MIBC), KEYNOTE-B96 (ovarian). #BCSM #Bladdercancer #gusm #ovariancancer #gynsm
The addition of local consolidative therapy to osimertinib improved PFS vs osimertinib alone in patients with EGFR-mutated locally advanced or metastatic #NSCLC (LBA72) NorthStar teial #ESMO25 bit.ly/4qnGuht #lcsm
Local consolidative therapy combined with osimertinib improves progression-free survival in metastatic EGFR-mutant NSCLC
Results from the NorthStar trial highlight the potential for integrating local therapy with targeted agents to extend disease control in this setting
dailyreporter.esmo.org
October 17, 2025 at 5:04 PM
The addition of local consolidative therapy to osimertinib improved PFS vs osimertinib alone in patients with EGFR-mutated locally advanced or metastatic #NSCLC (LBA72) NorthStar teial #ESMO25 bit.ly/4qnGuht #lcsm
Reposted by Sara R. Fagerlie, PhD, CHCP
At #ESMO25, explore how AI & digital tools are shaping oncology:
📌 AI-based image biomarkers
📌 Clinical trials in the age of AI
📌 Digital tools for off-site care
📌 ChatGPT & cancer care
📅 17–19 Oct
📌 AI-based image biomarkers
📌 Clinical trials in the age of AI
📌 Digital tools for off-site care
📌 ChatGPT & cancer care
📅 17–19 Oct
October 17, 2025 at 5:30 AM
At #ESMO25, explore how AI & digital tools are shaping oncology:
📌 AI-based image biomarkers
📌 Clinical trials in the age of AI
📌 Digital tools for off-site care
📌 ChatGPT & cancer care
📅 17–19 Oct
📌 AI-based image biomarkers
📌 Clinical trials in the age of AI
📌 Digital tools for off-site care
📌 ChatGPT & cancer care
📅 17–19 Oct
It’s here! #ESMO25 kicks off today — Packed agenda with important data, some practice changing. Check out studies that will presented in the 3 Presidential Symposia 👇
October 17, 2025 at 9:35 AM
It’s here! #ESMO25 kicks off today — Packed agenda with important data, some practice changing. Check out studies that will presented in the 3 Presidential Symposia 👇
Reposted by Sara R. Fagerlie, PhD, CHCP
Top 10 Breast Cancer Abstracts at ESMO25 - Suggested by Paolo Tarantino
@ptarantinomd.bsky.social
oncodaily.com/voices/esmo2...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #BreastCancer #ESMO25
@ptarantinomd.bsky.social
oncodaily.com/voices/esmo2...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #BreastCancer #ESMO25
Top 10 Breast Cancer Abstracts at ESMO25 - Suggested by Paolo Tarantino - OncoDaily
Top 10 Breast Cancer Abstracts at ESMO25 - Suggested by Paolo Tarantino / cancer, EMSO 2025, ESMO, ESMO25, Headlines, OncoDaily, Oncology, Paolo Tarantino
oncodaily.com
October 10, 2025 at 11:01 PM
Top 10 Breast Cancer Abstracts at ESMO25 - Suggested by Paolo Tarantino
@ptarantinomd.bsky.social
oncodaily.com/voices/esmo2...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #BreastCancer #ESMO25
@ptarantinomd.bsky.social
oncodaily.com/voices/esmo2...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #BreastCancer #ESMO25
“We have a tendency to try to find a one-size-fits-all answer, and hormone therapy is one of the best examples of where one-size-fits-all answers do not work and lead to harmful decision making” @jama.com bit.ly/4mO0Qxr #medsky #womenshealth #menopause
Hormone Therapy for Menopause—A New Analysis of Old Data
This Medical News article discusses a new analysis of Women’s Health Initiative data that may help strengthen the understanding of menopausal hormone therapy’s benefits and risks for symptomatic women...
bit.ly
September 22, 2025 at 8:24 PM
“We have a tendency to try to find a one-size-fits-all answer, and hormone therapy is one of the best examples of where one-size-fits-all answers do not work and lead to harmful decision making” @jama.com bit.ly/4mO0Qxr #medsky #womenshealth #menopause
Reposted by Sara R. Fagerlie, PhD, CHCP
Functional high-risk (FHR) myeloma (relapse< 18 months) is an unmet medical need in MM. Katja Weisel, MD, spoke about how patients at FHR may be identified and encouraged CAR-T consideration for FHR patients at first relapse. #IMS25
September 20, 2025 at 2:35 PM
Functional high-risk (FHR) myeloma (relapse< 18 months) is an unmet medical need in MM. Katja Weisel, MD, spoke about how patients at FHR may be identified and encouraged CAR-T consideration for FHR patients at first relapse. #IMS25
What’s behind the rise in GI cancers among young adults?
Dr Marshall explores this in our latest #OncologyUnscripted.
🎥 Watch here: clinicalcaresolutions.net/activities/o...
#GIcancer #CancerCare #MedSky #OncSky #CanSky #CRC
Dr Marshall explores this in our latest #OncologyUnscripted.
🎥 Watch here: clinicalcaresolutions.net/activities/o...
#GIcancer #CancerCare #MedSky #OncSky #CanSky #CRC
September 12, 2025 at 8:10 PM
What’s behind the rise in GI cancers among young adults?
Dr Marshall explores this in our latest #OncologyUnscripted.
🎥 Watch here: clinicalcaresolutions.net/activities/o...
#GIcancer #CancerCare #MedSky #OncSky #CanSky #CRC
Dr Marshall explores this in our latest #OncologyUnscripted.
🎥 Watch here: clinicalcaresolutions.net/activities/o...
#GIcancer #CancerCare #MedSky #OncSky #CanSky #CRC
Final OS from FLAURA2 at #WCLC25:
osimertinib + chemo vs osimertinib alone in untreated advanced EGFR-mutated NSCLC.
👉 Median OS: 47.5 vs 37.6 mo (HR 0.77; p=0.02)
👉 3-yr OS: 63% vs 51% www.cancercommunicator.com/post/wclc25-... #LungCancer #NSCLC #Oncology #LCSM #CanSky #OncSky #MedSky
osimertinib + chemo vs osimertinib alone in untreated advanced EGFR-mutated NSCLC.
👉 Median OS: 47.5 vs 37.6 mo (HR 0.77; p=0.02)
👉 3-yr OS: 63% vs 51% www.cancercommunicator.com/post/wclc25-... #LungCancer #NSCLC #Oncology #LCSM #CanSky #OncSky #MedSky
#WCLC25: Four-Year Median OS with Osimertinib/Chemotherapy Combination in Advanced EGFR-Mutation Positive NSCLC
The final overall survival (OS) analysis from the FLAURA2 trial was presented during the International Association for the Study of Lung Cancer (IASLC) 2025 World Conference on Lung Cancer (WCLC) Pres...
www.cancercommunicator.com
September 8, 2025 at 9:59 PM
Final OS from FLAURA2 at #WCLC25:
osimertinib + chemo vs osimertinib alone in untreated advanced EGFR-mutated NSCLC.
👉 Median OS: 47.5 vs 37.6 mo (HR 0.77; p=0.02)
👉 3-yr OS: 63% vs 51% www.cancercommunicator.com/post/wclc25-... #LungCancer #NSCLC #Oncology #LCSM #CanSky #OncSky #MedSky
osimertinib + chemo vs osimertinib alone in untreated advanced EGFR-mutated NSCLC.
👉 Median OS: 47.5 vs 37.6 mo (HR 0.77; p=0.02)
👉 3-yr OS: 63% vs 51% www.cancercommunicator.com/post/wclc25-... #LungCancer #NSCLC #Oncology #LCSM #CanSky #OncSky #MedSky
Reposted by Sara R. Fagerlie, PhD, CHCP
MARIPOSA phase 3 trial: In advanced non–small-cell lung cancer with EGFR mutations, amivantamab–lazertinib led to longer overall survival than osimertinib but was associated with an increased risk of adverse events of grade 3 or higher. nej.md/4p6j53k
#WCLC25 | @iaslc.bsky.social
#WCLC25 | @iaslc.bsky.social
September 7, 2025 at 6:52 AM
MARIPOSA phase 3 trial: In advanced non–small-cell lung cancer with EGFR mutations, amivantamab–lazertinib led to longer overall survival than osimertinib but was associated with an increased risk of adverse events of grade 3 or higher. nej.md/4p6j53k
#WCLC25 | @iaslc.bsky.social
#WCLC25 | @iaslc.bsky.social
📢 Introducing Cancer Conference Hub
Follow real-time updates from the world’s leading hematology and oncology meetings — ASCO, ESMO, ASH, EHA, WCLC, SOHO, SABCS, AACR, and more.
👉 Explore the hub here: bsky.app/profile/did:...
Follow real-time updates from the world’s leading hematology and oncology meetings — ASCO, ESMO, ASH, EHA, WCLC, SOHO, SABCS, AACR, and more.
👉 Explore the hub here: bsky.app/profile/did:...
September 6, 2025 at 5:58 PM
📢 Introducing Cancer Conference Hub
Follow real-time updates from the world’s leading hematology and oncology meetings — ASCO, ESMO, ASH, EHA, WCLC, SOHO, SABCS, AACR, and more.
👉 Explore the hub here: bsky.app/profile/did:...
Follow real-time updates from the world’s leading hematology and oncology meetings — ASCO, ESMO, ASH, EHA, WCLC, SOHO, SABCS, AACR, and more.
👉 Explore the hub here: bsky.app/profile/did:...
Catch the latest updates from #WCLC25 — clinical data, expert insights, and practice-changing news, all in one place.
👉 Follow the curated feed here: Cancer Communicator | WCLC25
#LCSM #LungCancer #NSCLC #SCLC #CancerNews #Oncsky #Medsky #Cansky
👉 Follow the curated feed here: Cancer Communicator | WCLC25
#LCSM #LungCancer #NSCLC #SCLC #CancerNews #Oncsky #Medsky #Cansky
September 6, 2025 at 5:50 PM
Catch the latest updates from #WCLC25 — clinical data, expert insights, and practice-changing news, all in one place.
👉 Follow the curated feed here: Cancer Communicator | WCLC25
#LCSM #LungCancer #NSCLC #SCLC #CancerNews #Oncsky #Medsky #Cansky
👉 Follow the curated feed here: Cancer Communicator | WCLC25
#LCSM #LungCancer #NSCLC #SCLC #CancerNews #Oncsky #Medsky #Cansky
There are so many medical conferences held in Florida including this year's @ash.hematology.org annual meeting. Should we stop holding medical conferences in Florida? If they don't follow the evidence, why should the evidence be presented there? #medsky www.nytimes.com/2025/09/03/u...
Florida Says It Plans to End All Vaccine Mandates
www.nytimes.com
September 3, 2025 at 5:35 PM
There are so many medical conferences held in Florida including this year's @ash.hematology.org annual meeting. Should we stop holding medical conferences in Florida? If they don't follow the evidence, why should the evidence be presented there? #medsky www.nytimes.com/2025/09/03/u...
"Independent rural hospitals are increasingly joining what are called clinically integrated networks, collaborative groups that allow them to avoid selling out to larger health systems while sharing resources to save money and improve patient care" #medsky #hospitalhealth www.npr.org/sections/sho...
How rural hospitals are banding together to survive
Independent and rural hospitals are collaborating with their neighbors to shore up their finances instead of joining larger health systems to stay afloat.
www.npr.org
September 3, 2025 at 3:05 PM
"Independent rural hospitals are increasingly joining what are called clinically integrated networks, collaborative groups that allow them to avoid selling out to larger health systems while sharing resources to save money and improve patient care" #medsky #hospitalhealth www.npr.org/sections/sho...
While I don't disagree with the majority of this, I think the models, even if they stay exactly as they are (which the won't), will be sufficiently disruptive to our everyday lives-once organizations figure out how to use them to save $$ (which they haven't) www.nytimes.com/2025/09/03/o... #AI
Opinion | The Fever Dream of Imminent ‘Superintelligence’ Is Finally Breaking
www.nytimes.com
September 3, 2025 at 2:52 PM
While I don't disagree with the majority of this, I think the models, even if they stay exactly as they are (which the won't), will be sufficiently disruptive to our everyday lives-once organizations figure out how to use them to save $$ (which they haven't) www.nytimes.com/2025/09/03/o... #AI
WA, OR, and CA health alliance formed recognizing the importance of independent science and medicine. It's unfathomable what has happened at one of our most revered institutions. www.nytimes.com/2025/09/03/u... #medsky #cdc
Snubbing Kennedy, States Announce Plans to Coordinate on Vaccines
www.nytimes.com
September 3, 2025 at 2:36 PM
WA, OR, and CA health alliance formed recognizing the importance of independent science and medicine. It's unfathomable what has happened at one of our most revered institutions. www.nytimes.com/2025/09/03/u... #medsky #cdc
"Patients initiating semaglutide or tirzepatide had a more than 40% lower risk of hospitalization for heart failure or all-cause mortality compared with sitagliptin...In a head-to-head comparison, tirzepatide showed no meaningful benefit over semaglutide." #medsky #obesitymedicine bit.ly/41xqRcq
Semaglutide and Tirzepatide in Patients With Heart Failure With Preserved Ejection Fraction
This study evaluates the effectiveness and safety of semaglutide and tirzepatide in patients with cardiometabolic heart failure with preserved ejection fraction in clinical practice.
jamanetwork.com
August 31, 2025 at 6:04 PM
"Patients initiating semaglutide or tirzepatide had a more than 40% lower risk of hospitalization for heart failure or all-cause mortality compared with sitagliptin...In a head-to-head comparison, tirzepatide showed no meaningful benefit over semaglutide." #medsky #obesitymedicine bit.ly/41xqRcq
"Health care is exceptional among U.S. markets in that profits and value often don’t align...When quality is hard to assess, market power is sizable, and patients are vulnerable, corporatization carries the risk of increasing prices or reducing quality." #medsky www.nejm.org/doi/full/10....
The Corporatization Deal — Health Care, Investors, and the Profit Priority | NEJM
Corporatization represents a deal between medical organizations and investors and presumably benefits those entities. But the key question for society is whether it benefits patients and payers.
www.nejm.org
August 31, 2025 at 4:17 PM
"Health care is exceptional among U.S. markets in that profits and value often don’t align...When quality is hard to assess, market power is sizable, and patients are vulnerable, corporatization carries the risk of increasing prices or reducing quality." #medsky www.nejm.org/doi/full/10....
At a dr appt, I was asked permission to use an AI app to take notes. I was told the app would record, write up notes, and delete the recording. Thoughts on this, Especially with otterai class actuin lawsuit? Should we be signing informed consent? #MedSky #AIinHealthcare #HealthTech #DigitalHealth
Otter Meeting Agent - AI Notetaker, Transcription, Insights
Otter AI Meeting Agent supports real-time transcription, live chat, automated summaries, insights, and action items.
otter.ai
August 31, 2025 at 3:37 PM
At a dr appt, I was asked permission to use an AI app to take notes. I was told the app would record, write up notes, and delete the recording. Thoughts on this, Especially with otterai class actuin lawsuit? Should we be signing informed consent? #MedSky #AIinHealthcare #HealthTech #DigitalHealth
"since the widespread adoption of generative AI, early-career workers (ages 22-25) in the most AI-exposed occupations have experienced a 13 percent relative decline in employment even after controlling for firm-level shocks." digitaleconomy.stanford.edu/wp-content/u...
August 31, 2025 at 3:23 PM
"since the widespread adoption of generative AI, early-career workers (ages 22-25) in the most AI-exposed occupations have experienced a 13 percent relative decline in employment even after controlling for firm-level shocks." digitaleconomy.stanford.edu/wp-content/u...
$491 BILLION from MediCARE for an already fragile healthcare system "The CBO estimates that Medicare, the federal health insurance program for Americans over age 65, could potentially see as much as $491 billion from 2027 to 2034 if Congress does not act." #medsky
abcnews.go.com/US/wireStory...
abcnews.go.com/US/wireStory...
August 19, 2025 at 2:52 PM
$491 BILLION from MediCARE for an already fragile healthcare system "The CBO estimates that Medicare, the federal health insurance program for Americans over age 65, could potentially see as much as $491 billion from 2027 to 2034 if Congress does not act." #medsky
abcnews.go.com/US/wireStory...
abcnews.go.com/US/wireStory...
Reposted by Sara R. Fagerlie, PhD, CHCP
Large but retrospective study.
People that get Zoster after C19 are at risk of other serious illnesses over the three year follow-up.
www.nature.com/articles/s41...
People that get Zoster after C19 are at risk of other serious illnesses over the three year follow-up.
www.nature.com/articles/s41...
Cardiorenal outcomes after herpes zoster reactivation in COVID-19 survivors from a global TriNetX study - Scientific Reports
Scientific Reports - Cardiorenal outcomes after herpes zoster reactivation in COVID-19 survivors from a global TriNetX study
www.nature.com
August 17, 2025 at 9:51 AM
Large but retrospective study.
People that get Zoster after C19 are at risk of other serious illnesses over the three year follow-up.
www.nature.com/articles/s41...
People that get Zoster after C19 are at risk of other serious illnesses over the three year follow-up.
www.nature.com/articles/s41...